Whether IFNs upregulate ACE2 in putative target cell subsets in vivo will be of significant interest to define in future work once current COVID-19-related restrictions on basic scientific inquiry are lifted (Qian et al., 2013). The gene discussed is ACE2; the disease is COVID-19.